Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Resectable Non-Small Cell Lung Cancer 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Colonic Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × adagrasib × Clear all
NCT05634525 2025-07-25

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡